Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.49% | -18.37% | |||
| Total Other Revenue | 124.54% | -54.35% | |||
| Total Revenue | 21.36% | -20.07% | |||
| Cost of Revenue | 8.94% | -9.40% | |||
| Gross Profit | 39.35% | -31.72% | |||
| SG&A Expenses | 0.19% | -20.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.66% | -12.46% | |||
| Operating Income | 80.38% | -40.76% | |||
| Income Before Tax | 67.81% | -5.54% | |||
| Income Tax Expenses | 31.98% | 138.37% | |||
| Earnings from Continuing Operations | 72.08% | -11.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.08% | -11.88% | |||
| EBIT | 80.38% | -40.76% | |||
| EBITDA | 67.55% | -36.22% | |||
| EPS Basic | 74.70% | -11.13% | |||
| Normalized Basic EPS | 66.97% | -34.68% | |||
| EPS Diluted | 76.20% | -9.91% | |||
| Normalized Diluted EPS | 68.41% | -33.71% | |||
| Average Basic Shares Outstanding | -1.50% | -0.84% | |||
| Average Diluted Shares Outstanding | -2.34% | -2.28% | |||
| Dividend Per Share | 0.00% | -- | |||
| Payout Ratio | -0.43% | -- | |||